Sinonasal mucosal melanoma: A 44-case study and literature analysis

Dréno, Marine; Georges, Marie des; Espitalier, F.; Ferron, C.; Charnolé, A.; Dréno, Brigitte; Malard, O.

doi:10.1016/j.anorl.2017.02.003

Cited by 36 publications

(59 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sinonasal mucosal melanoma (SNMM) accounts for 0.3-2% of all primary malignant melanomas ( 1 ), approximately 2-9% of head and neck mucosal melanomas ( 2 ) and 4-8% of all sinonasal malignancies ( 3 ). It affects patients in 5th to 8th decade of life ( 4 - 6 ), generally older than those with cutaneous melanoma ( 1 ), probably because of an increase in the number of melanocytes with advancing age ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

“…Most primary SNMMs (65.5-80.9%) arise within the nasal cavity ( 5 , 6 ), in particular in the nasal septum, the inferior and middle turbinate, the lateral nasal wall and the nasal floor ( 3 , 4 , 6 , 8 , 9 ). The paranasal sinuses are less frequently involved, usually the maxillary sinuses (15.1-16.9%), followed by the ethmoid sinus, the frontal sinus and sphenoid sinus ( 5 , 6 ).…”

Section: Introductionmentioning

confidence: 99%

“…The paranasal sinuses are less frequently involved, usually the maxillary sinuses (15.1-16.9%), followed by the ethmoid sinus, the frontal sinus and sphenoid sinus ( 5 , 6 ). The predominant manifestations of SNMMs are unilateral epistaxis and nasal obstruction ( 3 , 6 , 8 , 9 ). Symptoms vary according to tumor size and location ( 8 ) and advanced cases may present with enlargement causing nasal or facial deformity, facial pressure, pain, and less often frontal headache, hypoesthesia, unilateral hearing loss, rhinorrhea, hyposmia, congestion, breathing discomfort, diplopia, proptosis and epiphora ( 1 , 3 , 7 - 9 ).…”

Section: Introductionmentioning

confidence: 99%

“…The predominant manifestations of SNMMs are unilateral epistaxis and nasal obstruction ( 3 , 6 , 8 , 9 ). Symptoms vary according to tumor size and location ( 8 ) and advanced cases may present with enlargement causing nasal or facial deformity, facial pressure, pain, and less often frontal headache, hypoesthesia, unilateral hearing loss, rhinorrhea, hyposmia, congestion, breathing discomfort, diplopia, proptosis and epiphora ( 1 , 3 , 7 - 9 ). The indolent and non specific clinical appearance of SNMM may lead to a significant delay in diagnosis ( 1 , 8 , 9 ), which affects negatively the prognosis of the disease ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Recurrence in a patient with a 10-year history of sinonasal mucosal melanoma manifesting as facial swelling

et al. 2017

View full text Add to dashboard Cite

Sinonasal mucosal melanoma is a rare tumor that develops slowly and may manifest with non specific signs and symptoms, causing significant delay in diagnosis. Local recurrence is common and usually occurs within the first two years after the initial treatment. Prognosis of recurrent lesions is poor and 5-year survival ranges between 10-47%. We report the clinical, radiographic, histopathological and immunohistochemical findings of a recurrent sinonasal mucosal melanoma which was diagnosed 10 years after the initial treatment, in a patient who presented with unilateral facial swelling and one-sided difficulty in breathing of two years duration. We discuss the causes of late diagnosis and review the negative predictive factors for recurrence and survival. As early diagnosis is of paramount importance for prognosis, we emphasize the signs and symptoms of patients with a history of sinonasal mucosal melanoma which should raise the suspicion for recurrence, in spite of a long time interval since diagnosis. Key words: Mucosal melanoma, nasal cavity, sinus, recurrence.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Recurrence in a patient with a 10-year history of sinonasal mucosal melanoma manifesting as facial swelling

et al. 2017

View full text Add to dashboard Cite

show abstract

“…1 It has a poor prognosis with a median survival of approximately 19 months and 5-year survival of 20% to 35%. [1][2][3][4][5][6] The optimal treatment strategy for SNM remains undefined. Currently, the standard of care is surgical resection with little benefit from radiotherapy and few options for systemic therapy.…”

mentioning

confidence: 99%

Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma

Klebaner

Saddawi‐Konefka

Finegersh

et al. 2020

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background Although treatment with checkpoint blockade is now accepted as standard of care for cutaneous melanoma, few studies have investigated its role in sinonasal melanoma (SNM). We aimed to evaluate whether immunotherapy was associated with improved survival in SNM and to compare the effect of immunotherapy in metastatic sinonasal and cutaneous melanoma. Methods This was a cohort study of patients included in the United States National Cancer Database who had been diagnosed with sinonasal or cutaneous melanoma between 2012 and 2015 and had complete information regarding immunotherapy status. The primary outcome was overall survival. The influence of immunotherapy on overall survival was compared by Kaplan‐Meier and Cox proportional hazards models. Propensity score matched analyses between SNM patients who received immunotherapy and those who did not were based on clinicopathological covariates associated with survival in univariate Cox models. Results The analytic cohort consisted of 704 patients with SNM, 94 of whom were treated with immunotherapy and 152,896 patients with cutaneous melanoma, 8055 of whom were treated with immunotherapy. Immunotherapy was not associated with survival in the propensity‐score matched cohort (n = 195; hazard ratio [HR] = 1.0; 95% confidence interval [CI], 0.7 to 1.5; p = 0.88) or in adjusted Cox proportional hazards model (n = 549; HR = 1.0; 95% CI, 0.74 to 1.4; p = 0.88). Regimens including immunotherapy were associated with improved overall survival in metastatic cutaneous melanoma (HR = 0.57; 95% CI, 0.49 to 0.66; p < 0.0001), but not metastatic SNM (HR = 1.1; 95% CI, 0.67 to 1.7; p = 0.75). Conclusion Compared to current standard of care therapy, inclusion of immunotherapy as first‐line therapy was not associated with improved survival in SNM.

show abstract

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Kuan

Wang

Adappa

et al. 2024

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

BackgroundSinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represents a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.MethodsIn accordance with prior ICAR documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.ResultsThe ICNST document consists of 4 major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.ConclusionAs an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.This article is protected by copyright. All rights reserved

show abstract

Sinonasal mucosal melanoma: A 44-case study and literature analysis

Cited by 36 publications

References 25 publications

Recurrence in a patient with a 10-year history of sinonasal mucosal melanoma manifesting as facial swelling

Recurrence in a patient with a 10-year history of sinonasal mucosal melanoma manifesting as facial swelling

Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Contact Info

Product

Resources

About